Skip to content

house · Committee report

H. Rept. 119-160

SHANDRA EISENGA HUMAN CELL AND TISSUE PRODUCT SAFETY ACT

2025-06-12

Committees

Associated legislation

Text

Purpose and Summary

H.R. 1082 comes as a response to the passing of Shandra Eisenga of Marion, Michigan due to complications from a tuberculosis infection after receiving a tissue donation from an infected donor.\1\ The bill would help educate and inform healthcare providers and other healthcare professionals regarding human cell and tissue product transplants and donations through a public awareness campaign. The bill would provide the Food and Drug Administration (FDA) enforcement authority, through the issuance of civil monetary penalties, for violations of donor eligibility requirements and good tissue practices. It would also direct FDA to take additional steps to promote public health by publishing educational materials, best practices, and other relevant information on FDA's public website, as well as by conducting workshops and other educational sessions for relevant stakeholders and establish a public docket for related comments. Lastly, the bill would require the Secretary of Health and Human Services (HHS) to report to Congress on recommendations for the regulation of human cell and tissue products. --------------------------------------------------------------------------- \1\Melissa Nann Burke, House passes bill after TB death of Michigan woman who received tainted bone graft material, The Detroit News (December 16, 2024), https://www.detroitnews.com/story/news/local/ michigan/2024/12/16/michigan-woman-dies-tuberculosis-tb-death- contaminated-bone-graft-material-congress-bill/77031681007/; See also Jonathan M. Wortham, MD et al., Second Nationwide Tuberculosis Outbreak Caused by Bone Allografts Containing Live Cells--United States, 2023, Centers for Disease Control and Prevention Morbidity & Mortality Weekly Report, Vol. 72, No. 52-53 (Jan. 5, 2024), https://www.cdc.gov/mmwr/ volumes/72/wr/pdfs/mm725253-H.pdf. ---------------------------------------------------------------------------

Background and Need for Legislation

Ms. Eisenga was one of 36 patients across seven states to contract tuberculosis from a tissue donation originating from an infected donor, resulting in two deaths.\2\ This bill will increase public awareness, patient safety, and public trust in these lifesaving medical products to help ensure this preventable tragedy occurred for the last time. --------------------------------------------------------------------------- \2\Id. ---------------------------------------------------------------------------

Committee Action

On February 29, 2024, the Subcommittee on Health held a hearing on H.R. 7188.\3\ The title of the hearing was ``Legislative Proposals to Support Patients with Rare Diseases.'' The Subcommittee received testimony from: --------------------------------------------------------------------------- \3\Provisions of H.R. 7188 were reintroduced in the 119th Congress as H.R. 1082. --------------------------------------------------------------------------- Terence Flotte, MD, Provost and Dean of UMass Chan Medical School, Vice President of American Society of Gene and Cell Therapy (ASGCT); Alexander Bassuk, MD, PhD, Physician-in- Chief, University of Iowa Stead Family Children's Hospital; Chair and Professor, Stead Family Department of Pediatrics; Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital; Jeromie Ballreich, PhD, Associate Research Professor, Johns Hopkins Bloomberg School of Public Health; Alice Chen, PhD, Senior Fellow, USC Schaeffer Center for Health Policy and Economics; Associate Professor and Vice Dean for Research, USC Sol Price School of Public Policy; and Khrystal Davis, JD, Founding President, Texas Rare Alliance. On May 16, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 7188, as amended, to the full Committee by a record vote of 27 yeas to 0 nays. On September 18, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 7188, as amended, favorably reported to the House by a record vote of 40 yeas and 0 nays. On April 29, 2025, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 1082 favorably reported to the House by voice vote.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. There were no record votes taken in connection with ordering H.R. 1082 reported. Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 1082 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to increase public awareness, patient safety, and public trust in human cell and tissue products. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 1082 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 1082: On February 29, 2024, the Subcommittee on Health held a hearing on H.R. 7188.\4\ The title of the hearing was ``Legislative Proposals to Support Patients with Rare Diseases.'' The Subcommittee received testimony from: --------------------------------------------------------------------------- \4\Provisions of H.R. 7188 were reintroduced in the 119th Congress as H.R. 1082. --------------------------------------------------------------------------- Terence Flotte, MD, Provost and Dean of UMass Chan Medical School, Vice President of American Society of Gene and Cell Therapy (ASGCT); Alexander Bassuk, MD, PhD, Physician-in-Chief, University of Iowa Stead Family Children's Hospital; Chair and Professor, Stead Family Department of Pediatrics; Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital; Jeromie Ballreich, PhD, Associate Research Professor, Johns Hopkins Bloomberg School of Public Health; Alice Chen, PhD, Senior Fellow, USC Schaeffer Center for Health Policy and Economics; Associate Professor and Vice Dean for Research, USC Sol Price School of Public Policy; and Khrystal Davis, JD, Founding President, Texas Rare Alliance. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 1082 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title This section provides that the Act may be cited as the ``Shandra Eisenga Human Cell and Tissue Product Safety Act.'' Section 2. Definitions This section provides the meaning of the terms present in the bill. Section 3. Human cell and tissue products transplant public awareness campaign This section would require the Secretary of Health and Human Services (HHS) to conduct a national education campaign to increase public and health care provider awareness regarding human cell and tissue product transplants and donations. Section 4. Civil penalties for violation of requirements for human cell and tissue products This section provides the Food and Drug Administration (FDA) enforcement authority, through issuance of civil monetary penalties, for violations of donor eligibility requirements and good tissue practices with respect to human cell and tissue products. Section 5. Streamlining regulatory oversight of human cell and tissue products This section would direct FDA to take additional steps to provide information on regulatory oversight of human cell and tissue products, including by publishing educational materials, best practices, and other relevant information on FDA's public website, as well as by conducting workshops and other educational sessions for relevant stakeholders, and establish a public docket for related comments. Lastly, the bill would require the Secretary of HHS to report to Congress on recommendations for the regulation of human cell and tissue products. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE * * * * * * * Part G--Quarantine and Inspection * * * * * * * penalties Sec. 368. (a) Any person who violates any regulation prescribed under section 361, 362, or 363, or any provision of section 366 or any regulation prescribed thereunder, or who enters or departs from the limits of any quarantine station, ground, or anchorage in disregard of quarantine rules and regulations or without permission of the quarantine officer in charge, shall be punished by a fine of not more than $1,000 or by imprisonment for not more than one year, or both. (b) Any vessel which violates section 366, or any regulations thereunder or under section 364, or which enters within or departs from the limits of any quarantine station, ground, or anchorage in disregard of the quarantine rules and regulations or without permission of the officer in charge, shall forfeit to the United States not more than $5,000, the amount to be determined by the court, which shall be a lien on such vessel, to be recovered by proceedings in the proper district court of the United States. In all such proceedings the United States attorney shall appear on behalf of the United States; and all such proceedings shall be conducted in accordance with the rules and laws governing cases of seizure of vessels for violation of the revenue laws of the United States. (c) With the approval of the Secretary, the Surgeon General may, upon application therefor, remit or mitigate any forfeiture provided for under subsection (b) of this section, and he shall have authority to ascertain the facts upon all such applications. (d)(1) Any person who, on or after the date of the enactment of the Shandra Eisenga Human Cell and Tissue Product Safety Act, violates a requirement of subparts C or D of section 1271 of title 21, Code of Federal Regulations, (or successor regulations) with respect to human cell or tissue products regulated under section 361 shall be liable to the United States for a civil penalty in an amount not to exceed the sum of-- (A)(i) $20,000 for each violation; and (ii) in the case of a violation that continues after the Secretary provides written notice to such person, $20,000 for each subsequent day on which the violation continues; and (B) an amount equal to the retail value of the human cell and tissue products that are the subject of the violation. (2) The total civil penalty under paragraph (1) may not exceed $10,000,000 for all such violations adjudicated in a single proceeding. (3) In this subsection, the term ``human cell and tissue products'' has the meaning given the term ``human cells, tissues, or cellular or tissue-based products'' in section 1271.3(d) of title 21, Code of Federal Regulations (or successor regulations). * * * * * * * ---------- FOOD AND DRUG OMNIBUS REFORM ACT OF 2022 * * * * * * * DIVISION FF--HEALTH AND HUMAN SERVICES * * * * * * * TITLE III--FOOD AND DRUG ADMINISTRATION * * * * * * * Subtitle B--Drugs and Biologics CHAPTER 1--RESEARCH, DEVELOPMENT, AND COMPETITION IMPROVEMENTS * * * * * * * SEC. 3205. PUBLIC WORKSHOP ON CELL THERAPIES. Not later than 3 years after the date of the enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs, shall convene a public workshop with relevant stakeholders to discuss [best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue-, and cellular-based medical products (and the latest scientific information about such products) that are regulated as drugs under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and biological products under section 351 of the Public Health Service Act (42 U.S.C. 262), namely, stem cell and other cellular therapies] best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue-, and cellular-based medical products (and the latest scientific information about such products), namely, stem cell and other cellular therapies. * * * * * * * [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/160